Your session is about to expire
← Back to Search
Group 1 RSVt Vaccine for RSV vaccination (PEARL Trial)
PEARL Trial Summary
"This trial will test a new vaccine for Respiratory Syncytial Virus in children between 6 months and 22 months old. The study will involve about 6300 children across multiple countries and centers
PEARL Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.PEARL Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any vacancies available for patients to participate in this trial?
"As per information on clinicaltrials.gov, this research project is presently in search of eligible participants. The trial's initial posting was dated February 6th, 2024, with the most recent edit made on March 15th, 2024."
Is there an age limit that excludes individuals above 60 years old from participating in this medical study?
"Participants aged over 6 months and under 21 months are eligible for inclusion in the study."
Which individuals meet the criteria for participation in this medical study?
"This study aims to enroll 6300 individuals who have received the RSV vaccine and are between 6 months and less than 22 months of age. To be eligible, participants must: - Be aged from their sixth month up to but not including their twenty-second month on the day of recruitment (from six months after birth until one day before turning twenty-two months), - Demonstrate good health following a medical assessment, with a complete medical history evaluation, - Have been born after completing at least thirty-seven weeks of pregnancy."
How prevalent is the participation of medical centers in North America for this particular study?
"The research is conducted at Investigational Site Number 0320002 in San Miguel de Tucumán, Tucumán; Maximos OB/GYN in League City, Texas; and Investigational Site Number 3400001 in San Pedro Sula, Idaho. Additionally, the study extends to eight other undisclosed locations."
Has the Group 1 RSVt Vaccine received official authorization from the FDA?
"According to our evaluation at Power, the safety rating for Group 1 RSVt Vaccine is graded as a 3 on the scale due to its Phase 3 trial status, indicating evidence of both efficacy and robust safety data."
Share this study with friends
Copy Link
Messenger